SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jesspro who wrote (4131)2/11/2016 10:50:40 PM
From: jaybe1 Recommendation

Recommended By
mulanoon2007

  Read Replies (1) of 4474
 
Surprising to see dasatinib with highest VOE risk factor, makes me doubt the comparison. In any case only the prospective head-to-head data from OPTIC2L will settle anything at this point, and with only 3 countries enrolling to date (Belgium, Hungary, and Spain) this is likely an ASH 2017 event.

IMO the 30mg-->15mg arm will show higher MMR rate vs. nilo, ~65% vs. ~45% (mainly due to capturing T315I resistance), with comparable VOEs (14-18%?), and the 15mg-->10mg arm will show comparable MMR with lower VOEs (8-12%?). Note the trial is randomized 2:1 for lower dose arm (15mg--->10mg), which will have the effect of averaging down overall rates for all AEs, a much needed dataset for pona's profile. IMO this will set the stage for starting all 2L patients on 15mg, monitoring BCR-ABL, and dosing up to 30mg or down to 10mg as required to achieve and maintain optimal responses.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News